Supply Chain Ecosystem Analysis now part of DBMR Reports
Market Size in USD Billion
| 2025 –2032 | |
|
|
USD 1.02 Million |
| USD 1.21 Million | |
| % | |
|
Middle East and Africa Cyclodextrins in Pharma Market Segmentation, By Type (Β Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α Cyclodextrin, γ-Cyclodextrin, Randomly Methylated Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin and 2-Hydroxypropyl-Γ-Cyclodextrin), Structure (Cyclodextrin Conjugates, Mucoadhesive Drug Carriers, Cyclodextrin Associates, Amphiphilic Cyclodextrins and Others), Nature (Hydrophilic and Hydrophobic), Form (Solid and Liquid), Application (Drug Solubility and Dissolution, Drug Bioavailability, Drug Safety, Drug Stability and Others), Therapeutic Areas (Pain Management, Cardiovascular Diseases, Behavioral Disorder, Cancer Therapy, Rheumatoid Arthritis, Epilepsy, Niemann Pick Disease Type C (NPC) and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others) - Industry Trends and Forecast to 2032
Get Exclusive Sample Copy of this Report Here
|
Attributes
|
Middle East and Africa Cyclodextrins in Pharma Key Market Insights
|
|
Segments Covered
|
|
|
Countries Covered
|
Middle East and Africa
|
|
Key Market Players
|
|
|
Market Opportunities
|
|
|
Value Added Data Infosets
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, pricing analysis, brand share analysis, consumer survey, demography analysis, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.
|
Enhanced Drug Delivery and Solubility Solutions
Driver
Rising Demand Due to Chronic Disease Prevalence and Pharmaceutical Advancements
Restraint/Challenge
High Production Costs and Regulatory Compliance Hurdles
The market is segmented on the basis of type, structure, nature, form, application, therapeutic areas, and distribution channel.
On the basis of type, the market is segmented into Β Cyclodextrin, 2-Hydroxypropyl-Β-Cyclodextrin, Α Cyclodextrin, γ-Cyclodextrin, Randomly Methylated Β-Cyclodextrin, Sulfobutylether Β-Cyclodextrin, and 2-Hydroxypropyl-Γ-Cyclodextrin. The Β Cyclodextrin segment dominated the market with the largest share of 42.5% in 2024, primarily due to its wide pharmaceutical applicability in enhancing solubility and stability of poorly soluble drugs. Its cost-effectiveness and established safety profile have encouraged adoption in generic formulations across Middle East and Africa. The segment further benefits from being the most studied and commercially available cyclodextrin type, driving confidence among pharmaceutical manufacturers. Its use in oral solid dosage forms and parenteral formulations strengthens its role in the regional market. Moreover, regulatory familiarity with Β Cyclodextrin accelerates approvals and commercial rollouts. This has positioned it as the backbone of cyclodextrin applications in regional pharma pipelines.
The Sulfobutylether Β-Cyclodextrin (SBE-β-CD) segment is expected to witness the fastest growth from 2025 to 2032, driven by its unique ability to improve solubility and reduce toxicity of IV-administered drugs. Its increasing adoption in injectable formulations for cancer therapy, CNS disorders, and antifungal drugs is fueling demand. Multinational and local pharma companies in MEA are exploring SBE-β-CD for complex molecules that require advanced carriers. In addition, growing clinical trial activities in oncology and rare disease therapies are accelerating the adoption of SBE-β-CD. Its patent-protected niche applications also allow companies to generate higher value margins. This segment is therefore poised to expand rapidly as biologics and specialty pharma products gain traction in the region.
On the basis of structure, the market is segmented into cyclodextrin conjugates, mucoadhesive drug carriers, cyclodextrin associates, amphiphilic cyclodextrins, and others. The Cyclodextrin Conjugates segment dominated the market in 2024 due to their ability to improve pharmacokinetics, controlled drug release, and therapeutic efficacy. In the Middle East and Africa, pharma manufacturers rely on conjugates to optimize performance of pain management and cardiovascular drugs. Their versatility in oral, injectable, and topical drug delivery systems provides wider adoption across therapeutic categories. In addition, research collaborations in Gulf countries are boosting innovation in conjugate-based platforms. Favorable clinical outcomes and broad-spectrum applicability ensure the segment’s dominance in the regional landscape. As patents expire on legacy drugs, conjugates provide opportunities for lifecycle management strategies.
The Amphiphilic Cyclodextrins segment is expected to grow fastest through 2032, driven by their efficiency in encapsulating hydrophobic drugs and enhancing bioavailability. This structure is gaining traction in oncology and CNS drug formulations, where solubility challenges are significant. Regional research hubs in South Africa and the UAE are increasingly exploring amphiphilic carriers for advanced nanomedicine applications. Their role in targeted drug delivery and sustained release further expands their potential. In addition, partnerships with European biotech firms are bringing innovative amphiphilic CD-based products into MEA markets. The growing emphasis on precision medicine will continue to accelerate demand in this subsegment.
On the basis of nature, the market is segmented into hydrophilic and hydrophobic. The Hydrophilic segment dominated the market in 2024, accounting for the majority share due to its wide adoption in solubility enhancement and safety improvement of various hydrophobic drugs. Pharmaceutical companies in MEA prefer hydrophilic cyclodextrins for their strong inclusion complexation ability, which improves stability and absorption of APIs. Their compatibility with multiple dosage forms such as injectables, tablets, and eye drops supports higher penetration. Hospitals and generics manufacturers leverage hydrophilic CDs to create cost-effective yet efficient drug formulations. In addition, established clinical safety records ensure wider regulatory acceptance in the region. This has cemented hydrophilic CDs as the backbone of CD utilization.
The Hydrophobic segment is projected to expand fastest during 2025–2032, largely driven by its growing use in advanced formulations that require improved lipophilicity. Hydrophobic CDs are increasingly explored in oncology and CNS therapies where lipophilic drugs struggle with poor absorption. Their ability to enhance permeability and sustain drug release positions them well for novel formulations in MEA markets. Research initiatives in academic institutions across South Africa and Saudi Arabia are also boosting adoption. As pharma companies expand their specialty product portfolios, demand for hydrophobic carriers is expected to rise. Their emerging role in transdermal and targeted delivery systems further strengthens their growth trajectory.
On the basis of form, the market is segmented into solid and liquid. The Solid form dominated the market in 2024 due to its extensive use in oral dosage forms and ease of handling in large-scale manufacturing. Solid CDs are widely adopted in tablet, capsule, and powder formulations across Middle East and Africa. Their longer shelf-life, stability, and lower transportation costs make them attractive to both multinational and regional drugmakers. Moreover, solid CDs allow flexible integration into excipient blends, supporting versatility in generic and branded formulations. Their role in cost-efficient production further consolidates dominance in the regional market. As oral drugs remain the most prescribed form, solid CDs retain their strong position.
The Liquid form is projected to grow fastest during 2025–2032, supported by rising demand in parenteral and ophthalmic formulations. Intravenous and ophthalmic drug products often require liquid CDs for immediate solubilization and stabilization of APIs. Hospitals and specialty pharma players are increasingly adopting liquid CD-based injectables in cancer, antifungal, and cardiovascular treatments. Moreover, the growing biotech sector in MEA is exploring liquid cyclodextrins in monoclonal antibody formulations. Faster adoption is also driven by increased focus on pediatric and geriatric drug delivery systems requiring liquid solutions. This positions liquid CDs as a critical growth driver in advanced therapeutics.
On the basis of application, the market is segmented into drug solubility and dissolution, drug bioavailability, drug safety, drug stability, and others. The Drug Solubility and Dissolution segment dominated the market in 2024, as solubility challenges remain one of the biggest barriers for drug development in the Middle East and Africa. Cyclodextrins provide a proven solution by forming inclusion complexes that enhance solubility of poorly soluble drugs, making them highly preferred by generics manufacturers and research institutes. The dominance is reinforced by their wide usage across therapeutic categories, including oncology, cardiovascular, and pain management drugs. Regulatory approval pathways in MEA also favor solubility-enhancing technologies, further accelerating adoption. With oral solid dosage forms being the most common in the region, solubility-focused CD applications retain their market leadership. This strong reliance on CDs for overcoming solubility issues cements their dominance.
The Drug Bioavailability segment is anticipated to grow fastest from 2025 to 2032, fueled by the rising focus on enhancing therapeutic efficacy of advanced formulations. Poor bioavailability has been a limiting factor for lipophilic and biologic drugs, and cyclodextrins offer an effective pathway to overcome this barrier. Biotech and specialty pharma companies in MEA are increasingly investing in bioavailability enhancement to support precision medicine and novel drug delivery systems. Clinical trials involving oncology and rare disease therapies are also incorporating CDs to boost absorption rates. The segment’s growth is accelerated by collaborations with global CD suppliers introducing cutting-edge solutions. This positions bioavailability-enhancing CD applications as a key growth frontier in the region.
On the basis of therapeutic areas, the market is segmented into pain management, cardiovascular diseases, behavioral disorder, cancer therapy, rheumatoid arthritis, epilepsy, niemann pick disease Type C (NPC), and others. The Pain Management segment dominated the market in 2024, supported by the high burden of chronic pain conditions and widespread use of cyclodextrins in analgesic formulations. CDs improve solubility and stability of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids, enhancing their therapeutic profile. In the Middle East and Africa, pain management is a key therapeutic priority due to rising incidences of musculoskeletal disorders, post-operative pain, and cancer-related pain. The affordability and availability of CD-based formulations in both hospital and retail pharmacies further fuel adoption. Regional generics players actively incorporate CDs to differentiate their analgesic products. This entrenched role of CDs in pain relief therapies ensures the segment’s dominant share.
The Cancer Therapy segment is projected to grow fastest during 2025–2032, driven by the increasing focus on oncology drug development and precision medicine in MEA. CDs are critical in solubilizing lipophilic chemotherapeutics and stabilizing biologic agents, improving efficacy and reducing toxicity. Research institutes in South Africa, Egypt, and the Gulf region are actively exploring CD-based carriers for next-generation oncology therapies. Rising investments in clinical trials and partnerships with global pharma companies further drive growth. In addition, government initiatives to strengthen oncology care infrastructure are boosting demand for advanced formulations. The expanding role of CDs in targeted and combination therapies positions cancer therapy as the fastest-growing application.
On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others. The Hospital Pharmacy segment dominated the market in 2024, attributed to the large volume of CD-based injectable and specialty formulations dispensed through hospitals. Cyclodextrins are integral in parenteral drugs for cancer, cardiovascular, and infectious disease treatments, which are primarily distributed via hospital channels. In MEA, the rising number of hospital-based procurement programs ensures consistent demand for these formulations. Hospitals also lead in the adoption of newer CD-enabled therapies due to their access to clinical-grade supply chains. Furthermore, reimbursement policies in several MEA countries favor hospital-administered drugs, cementing their role in distribution. This positions hospital pharmacies as the primary channel for cyclodextrin-based products.
The Online Pharmacy segment is anticipated to grow fastest through 2032, fueled by increasing digital penetration and the adoption of e-health platforms across MEA. Post-pandemic, consumer behavior has shifted toward online purchases of both OTC and prescription drugs. CDs, often incorporated in oral and specialty formulations, are increasingly being sold via online portals catering to chronic disease patients and convenience-seeking buyers. Governments in countries such as UAE and Saudi Arabia are promoting e-pharmacy regulations, further legitimizing this channel. In addition, the growth of private online pharmacy startups is expanding patient access to advanced formulations. This makes online pharmacies the most dynamic growth channel for CD-based drugs in the forecast period.
South Africa Cyclodextrins in Pharma Market Insight
The South Africa cyclodextrins in pharma market is projected to grow at a substantial CAGR during the forecast period, supported by an advanced healthcare infrastructure and expanding clinical research activity. The country’s focus on innovation in drug delivery and its role as a leading pharmaceutical exporter within sub-Saharan Africa are driving demand. Cyclodextrins are gaining traction in oncology trials, biologic formulations, and controlled-release drugs. Rising awareness among healthcare providers and favorable regulatory support further strengthen South Africa’s position as a key growth market.
Saudi Arabia Cyclodextrins in Pharma Market Insight
The Saudi Arabia cyclodextrins in pharma market is anticipated to expand at a noteworthy CAGR during the forecast period, propelled by the Kingdom’s Vision 2030 strategy to localize pharmaceutical production. Increasing investments in healthcare infrastructure, R&D, and biotechnology are stimulating cyclodextrin use in advanced formulations. Rising incidences of chronic conditions such as cardiovascular diseases and diabetes are further driving demand for enhanced drug delivery solutions. With strong government backing and private sector investment, Saudi Arabia is emerging as a high-growth market for cyclodextrin applications.
United Arab Emirates Cyclodextrins in Pharma Market Insight
The UAE cyclodextrins in pharma market is expected to expand at a considerable CAGR, supported by its position as a regional hub for innovation and healthcare investment. The country’s emphasis on adopting advanced pharmaceutical technologies and forming strategic partnerships with global companies drives cyclodextrin adoption. A growing focus on specialty and rare disease treatments, coupled with high healthcare spending, promotes demand for solubility- and stability-enhancing excipients. The UAE’s robust logistics and distribution networks also facilitate easy access to cyclodextrins, supporting growth across both domestic and regional markets.
Nigeria Cyclodextrins in Pharma Market Insight
The Nigeria cyclodextrins in pharma market is poised to grow at one of the fastest CAGRs during the forecast period of 2025 to 2032, driven by its large population, rising burden of chronic diseases, and expanding local pharmaceutical sector. Increasing government efforts to reduce drug imports and encourage domestic production are creating opportunities for cyclodextrin adoption. Affordability-focused drug makers are beginning to leverage cyclodextrins to improve generic formulations. Growing investment in healthcare infrastructure and a strong demand for affordable yet effective therapies are expected to accelerate Nigeria’s role in regional market growth.
The Middle East and Africa Cyclodextrins in Pharma industry is primarily led by well-established companies, including:
SKU-
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.